What is BeOne Medicines Ltd.'s earnings per share (EPS)?

BeOne Medicines Ltd. (ONC) reported diluted earnings per share of $0.19 for fiscal year 2025. This represents a 140.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

BeOne Medicines Ltd. Financials

ONC

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows BeOne Medicines Ltd. (ONC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 67/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

BeOne Medicines Ltd. has an operating margin of 8.4%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 41/100, indicating healthy but not exceptional operating efficiency. This is up from -14.9% the prior year.

Growth

100

BeOne Medicines Ltd.'s revenue surged 40.2% year-over-year to $5.3B, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

BeOne Medicines Ltd. carries a low D/E ratio of 0.22, meaning only $0.22 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.41, BeOne Medicines Ltd. holds $3.41 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 66/100.

Cash Flow

BeOne Medicines Ltd. converts 17.6% of revenue into free cash flow ($941.7M). This strong cash generation earns a score of 69/100.

Returns

BeOne Medicines Ltd. generates a 6.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 26/100. This is up from -19.4% the prior year.

Altman Z-Score Safe

5.46

BeOne Medicines Ltd. scores 5.46, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($34.5B) relative to total liabilities ($3.8B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

BeOne Medicines Ltd. passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

3.93x

For every $1 of reported earnings, BeOne Medicines Ltd. generates $3.93 in operating cash flow ($1.1B OCF vs $286.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

9.0x

BeOne Medicines Ltd. earns $9.0 in operating income for every $1 of interest expense ($447.1M vs $50.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.3B

YoY+40.2%

5Y CAGR+76.8%

10Y CAGR+89.8%

BeOne Medicines Ltd. generated $5.3B in revenue in fiscal year 2025. This represents an increase of 40.2% from the prior year.

EBITDA

$588.8M

YoY+248.5%

BeOne Medicines Ltd.'s EBITDA was $588.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 248.5% from the prior year.

Net Income

$286.9M

YoY+144.5%

BeOne Medicines Ltd. reported $286.9M in net income in fiscal year 2025. This represents an increase of 144.5% from the prior year.

EPS (Diluted)

$0.19

YoY+140.4%

BeOne Medicines Ltd. earned $0.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 140.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$941.7M

YoY+248.7%

BeOne Medicines Ltd. generated $941.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 248.7% from the prior year.

Cash & Debt

$4.5B

YoY+73.1%

5Y CAGR+26.9%

10Y CAGR+74.0%

BeOne Medicines Ltd. held $4.5B in cash against $961.9M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

1.44B

YoY+4.0%

5Y CAGR+3.9%

10Y CAGR+28.6%

BeOne Medicines Ltd. had 1.44B shares outstanding in fiscal year 2025. This represents an increase of 4.0% from the prior year.

Margins & Returns

Gross Margin

87.5%

YoY+3.1pp

5Y CAGR+10.4pp

BeOne Medicines Ltd.'s gross margin was 87.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.

Operating Margin

8.4%

YoY+23.3pp

5Y CAGR+545.1pp

10Y CAGR+652.0pp

BeOne Medicines Ltd.'s operating margin was 8.4% in fiscal year 2025, reflecting core business profitability. This is up 23.3 percentage points from the prior year.

Net Margin

5.4%

YoY+22.3pp

5Y CAGR+531.5pp

10Y CAGR+653.1pp

BeOne Medicines Ltd.'s net profit margin was 5.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 22.3 percentage points from the prior year.

Return on Equity

6.6%

YoY+25.9pp

5Y CAGR+48.6pp

BeOne Medicines Ltd.'s ROE was 6.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 25.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.1B

YoY+9.9%

5Y CAGR+10.6%

10Y CAGR+43.4%

BeOne Medicines Ltd. invested $2.1B in research and development in fiscal year 2025. This represents an increase of 9.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$185.8M

YoY-62.3%

5Y CAGR+9.6%

10Y CAGR+42.7%

BeOne Medicines Ltd. invested $185.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 62.3% from the prior year.

ONC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.3B+40.2%	$3.8B+55.0%	$2.5B+73.7%	$1.4B+20.4%	$1.2B+280.8%	$308.9M
Cost of Revenue	N/A	N/A	N/A	$286.5M+73.7%	$164.9M+133.4%	$70.7M
Gross Profit	$4.7B+45.3%	$3.2B+54.7%	$2.1B+84.1%	$1.1B+11.7%	$1.0B+324.6%	$238.2M
R&D Expenses	$2.1B+9.9%	$2.0B+9.8%	$1.8B+8.4%	$1.6B+12.4%	$1.5B+12.7%	$1.3B
SG&A Expenses	$2.1B+13.7%	$1.8B+21.4%	$1.5B+17.9%	$1.3B+29.1%	$990.1M+65.0%	$600.2M
Operating Income	$447.1M+178.7%	-$568.2M+53.0%	-$1.2B+32.5%	-$1.8B-24.4%	-$1.4B+13.2%	-$1.7B
Interest Expense	$50.0M+6.5%	$46.9M+125.5%	$20.8M-4.1%	$21.7M-25.8%	$29.3M+59.8%	$18.3M
Income Tax	$129.9M+16.2%	$111.8M+100.1%	$55.9M+30.6%	$42.8M+122.5%	$19.2M+84.9%	$10.4M
Net Income	$286.9M+144.5%	-$644.8M+26.9%	-$881.7M+56.0%	-$2.0B-37.5%	-$1.5B+10.3%	-$1.6B
EPS (Diluted)	$0.19+140.4%	$-0.47+27.7%	$-0.65+56.4%	$-1.49-23.1%	$-1.21+19.3%	$-1.50

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$1.5B+6.1%	$1.4B+7.4%	$1.3B+17.7%	$1.1B-0.9%	$1.1B+12.6%	$1.0B+7.8%	$929.2M+23.6%	$751.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$1.4B+11.5%	$1.2B+5.7%	$1.2B+20.8%	$952.3M-1.5%	$967.3M+16.4%	$831.1M+5.1%	$791.0M+26.2%	$626.7M
R&D Expenses	$615.4M+17.5%	$523.7M-0.2%	$524.9M+8.9%	$481.9M-11.1%	$542.0M+9.2%	$496.2M+9.2%	$454.5M-1.3%	$460.6M
SG&A Expenses	$555.3M+5.0%	$529.0M-1.7%	$537.9M+17.1%	$459.3M-9.0%	$504.7M+10.9%	$455.2M+2.6%	$443.7M+3.8%	$427.4M
Operating Income	$185.0M+13.4%	$163.1M+85.6%	$87.9M+691.6%	$11.1M+114.0%	-$79.4M+34.0%	-$120.3M-12.2%	-$107.2M+59.0%	-$261.3M
Interest Expense	$12.3M-2.8%	$12.7M+5.0%	$12.0M-7.0%	$13.0M+86.6%	$6.9M-51.5%	$14.3M+8.2%	$13.2M+6.7%	$12.4M
Income Tax	$82.7M+270.6%	$22.3M+326.9%	$5.2M-73.4%	$19.6M-70.5%	$66.5M+188.7%	$23.0M+59.1%	$14.5M+87.5%	$7.7M
Net Income	$66.5M-46.7%	$124.8M+32.4%	$94.3M+7326.8%	$1.3M+100.8%	-$151.9M-25.2%	-$121.3M-0.8%	-$120.4M+52.1%	-$251.2M
EPS (Diluted)	N/A	$0.08+33.3%	$0.06	$0.00	N/A	$-0.090.0%	$-0.09+52.6%	$-0.19

ONC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.2B+38.3%	$5.9B+2.0%	$5.8B-9.0%	$6.4B-25.3%	$8.5B+52.4%	$5.6B
Current Assets	$6.2B+56.2%	$4.0B-5.0%	$4.2B-19.3%	$5.2B-31.6%	$7.6B+53.5%	$5.0B
Cash & Equivalents	$4.5B+73.1%	$2.6B-17.2%	$3.2B-18.0%	$3.9B-11.6%	$4.4B+216.6%	$1.4B
Inventory	$608.2M+22.9%	$495.0M+19.0%	$416.1M+47.4%	$282.3M+16.4%	$242.6M+171.7%	$89.3M
Accounts Receivable	$865.1M+27.9%	$676.3M+88.9%	$358.0M+106.8%	$173.2M-64.2%	$483.1M+699.8%	$60.4M
Goodwill	N/A	N/A	N/A	$109K0.0%	$109K0.0%	$109K
Total Liabilities	$3.8B+47.9%	$2.6B+14.1%	$2.3B+13.6%	$2.0B-16.9%	$2.4B+38.8%	$1.7B
Current Liabilities	$1.8B-17.4%	$2.2B+22.4%	$1.8B+23.3%	$1.5B-8.2%	$1.6B+48.8%	$1.1B
Long-Term Debt	$961.9M+477.8%	$166.5M-15.8%	$197.6M-5.5%	$209.1M+3.5%	$202.1M+10.1%	$183.6M
Total Equity	$4.4B+30.9%	$3.3B-5.8%	$3.5B-19.3%	$4.4B-28.5%	$6.1B+58.5%	$3.9B
Retained Earnings	-$8.3B+3.3%	-$8.6B-8.1%	-$8.0B-12.5%	-$7.1B-39.5%	-$5.1B-42.9%	-$3.6B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$8.2B+7.3%	$7.6B+21.2%	$6.3B+7.8%	$5.8B-1.3%	$5.9B+1.5%	$5.8B+2.1%	$5.7B+0.8%	$5.7B
Current Assets	$6.2B+10.0%	$5.7B+31.4%	$4.3B+10.6%	$3.9B-2.4%	$4.0B+2.0%	$3.9B+1.9%	$3.8B-1.8%	$3.9B
Cash & Equivalents	$4.5B+12.6%	$4.0B+46.5%	$2.8B+9.5%	$2.5B-4.2%	$2.6B-2.8%	$2.7B+4.2%	$2.6B-7.2%	$2.8B
Inventory	$608.2M+14.4%	$531.7M+5.7%	$502.9M+1.7%	$494.7M-0.1%	$495.0M+14.7%	$431.7M-2.6%	$443.3M-0.9%	$447.3M
Accounts Receivable	$865.1M+0.2%	$863.3M+12.0%	$770.8M+7.5%	$717.2M+6.1%	$676.3M+18.8%	$569.0M+7.5%	$529.4M+21.6%	$435.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.8B+9.3%	$3.5B+38.6%	$2.5B+7.9%	$2.3B-9.5%	$2.6B+8.1%	$2.4B+2.1%	$2.3B+1.7%	$2.3B
Current Liabilities	$1.8B-22.8%	$2.4B+7.2%	$2.2B+11.4%	$2.0B-10.4%	$2.2B+9.4%	$2.0B+4.5%	$1.9B+3.0%	$1.9B
Long-Term Debt	$961.9M	N/A	$146.1M-8.8%	$160.2M-3.8%	$166.5M-11.2%	$187.5M+1.2%	$185.3M-6.9%	$199.0M
Total Equity	$4.4B+5.6%	$4.1B+9.5%	$3.8B+7.7%	$3.5B+5.0%	$3.3B-3.0%	$3.4B+2.1%	$3.4B+0.2%	$3.4B
Retained Earnings	-$8.3B+0.8%	-$8.4B+1.5%	-$8.5B+1.1%	-$8.6B0.0%	-$8.6B-1.8%	-$8.5B-1.5%	-$8.3B-1.5%	-$8.2B

ONC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.1B+901.8%	-$140.6M+87.8%	-$1.2B+22.7%	-$1.5B-15.2%	-$1.3B-1.2%	-$1.3B
Capital Expenditures	$185.8M-62.3%	$492.7M-12.3%	$561.9M+72.7%	$325.4M+23.8%	$262.9M+123.8%	$117.5M
Free Cash Flow	$941.7M+248.7%	-$633.3M+63.2%	-$1.7B+5.6%	-$1.8B-16.7%	-$1.6B-11.5%	-$1.4B
Investing Cash Flow	-$276.2M+49.6%	-$548.4M-1013.9%	$60.0M-94.4%	$1.1B+68.1%	$640.7M+120.2%	-$3.2B
Financing Cash Flow	$1.1B+447.7%	$193.4M-53.6%	$416.5M+2295.3%	-$19.0M-100.5%	$3.6B-30.1%	$5.2B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$417.3M+3.7%	$402.6M+52.7%	$263.6M+498.0%	$44.1M-41.3%	$75.2M-60.1%	$188.4M+297.1%	-$95.6M+69.0%	-$308.6M
Capital Expenditures	$37.5M-22.0%	$48.1M+9.7%	$43.8M-22.3%	$56.4M-39.0%	$92.5M-30.8%	$133.7M+21.6%	$110.0M-29.8%	$156.6M
Free Cash Flow	$379.8M+7.2%	$354.5M+61.3%	$219.8M+1883.1%	-$12.3M+28.8%	-$17.3M-131.7%	$54.7M+126.6%	-$205.5M+55.8%	-$465.1M
Investing Cash Flow	-$38.3M+22.2%	-$49.3M+26.0%	-$66.6M+45.4%	-$121.9M-30.3%	-$93.6M+30.1%	-$133.9M-20.6%	-$111.0M+47.1%	-$209.8M
Financing Cash Flow	$96.9M-89.9%	$961.3M+2644.5%	$35.0M+203.7%	-$33.8M-646.8%	-$4.5M-135.7%	$12.7M-45.0%	$23.0M-85.8%	$162.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ONC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	87.5%+3.1pp	84.4%-0.1pp	84.5%+4.8pp	79.8%-6.2pp	86.0%+8.9pp	77.1%
Operating Margin	8.4%+23.3pp	-14.9%+34.2pp	-49.1%+77.3pp	-126.4%-4.1pp	-122.3%+414.4pp	-536.7%
Net Margin	5.4%+22.3pp	-16.9%+18.9pp	-35.9%+105.7pp	-141.5%-17.6pp	-123.9%+402.2pp	-526.1%
Return on Equity	6.6%+25.9pp	-19.4%+5.6pp	-24.9%+20.8pp	-45.7%-21.9pp	-23.8%+18.2pp	-42.0%
Return on Assets	3.5%+14.4pp	-10.9%+4.3pp	-15.2%+16.2pp	-31.4%-14.3pp	-17.1%+11.9pp	-29.0%
Current Ratio	3.41+1.6	1.80-0.5	2.32-1.2	3.55-1.2	4.76+0.1	4.61
Debt-to-Equity	0.22+0.2	0.050.0	0.060.0	0.05+0.0	0.03-0.0	0.05
FCF Margin	17.6%+34.3pp	-16.6%+53.3pp	-69.9%+58.7pp	-128.7%+4.1pp	-132.8%+320.8pp	-453.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	90.5%+4.4pp	86.1%-1.4pp	87.5%+2.3pp	85.2%-0.5pp	85.8%+2.8pp	83.0%-2.1pp	85.1%+1.7pp	83.4%
Operating Margin	12.3%+0.8pp	11.6%+4.9pp	6.7%+5.7pp	1.0%+8.0pp	-7.0%+5.0pp	-12.0%-0.5pp	-11.5%+23.2pp	-34.8%
Net Margin	4.4%-4.4pp	8.8%+1.7pp	7.2%+7.1pp	0.1%+13.6pp	-13.5%-1.3pp	-12.1%+0.8pp	-13.0%+20.5pp	-33.4%
Return on Equity	1.5%-1.5pp	3.0%+0.5pp	2.5%+2.5pp	0.0%+4.6pp	-4.6%-1.0pp	-3.5%+0.1pp	-3.6%+3.9pp	-7.5%
Return on Assets	0.8%-0.8pp	1.6%+0.1pp	1.5%+1.5pp	0.0%+2.6pp	-2.6%-0.5pp	-2.1%+0.0pp	-2.1%+2.3pp	-4.4%
Current Ratio	3.41+1.0	2.39+0.4	1.95-0.0	1.96+0.2	1.80-0.1	1.93-0.0	1.98-0.1	2.08
Debt-to-Equity	0.22-0.6	0.85+0.8	0.040.0	0.050.0	0.050.0	0.050.0	0.060.0	0.06
FCF Margin	25.4%+0.3pp	25.1%+8.4pp	16.7%+17.8pp	-1.1%+0.4pp	-1.5%-7.0pp	5.5%+27.6pp	-22.1%+39.8pp	-61.9%

Similar Companies

Argenx Se ARGX

$46.3B

Insmed Inc INSM

$35.0B

BIONTECH BNTX

$22.9B

Regeneron Pharmaceuticals REGN

$80.5B

Alnylam Pharmaceuticals Inc ALNY

$42.3B

Frequently Asked Questions

What is BeOne Medicines Ltd.'s annual revenue?

BeOne Medicines Ltd. (ONC) reported $5.3B in total revenue for fiscal year 2025. This represents a 40.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is BeOne Medicines Ltd.'s revenue growing?

BeOne Medicines Ltd. (ONC) revenue grew by 40.2% year-over-year, from $3.8B to $5.3B in fiscal year 2025.

Is BeOne Medicines Ltd. profitable?

Yes, BeOne Medicines Ltd. (ONC) reported a net income of $286.9M in fiscal year 2025, with a net profit margin of 5.4%.

What is BeOne Medicines Ltd.'s EBITDA?

BeOne Medicines Ltd. (ONC) had EBITDA of $588.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does BeOne Medicines Ltd. have?

As of fiscal year 2025, BeOne Medicines Ltd. (ONC) had $4.5B in cash and equivalents against $961.9M in long-term debt.

What is BeOne Medicines Ltd.'s gross margin?

BeOne Medicines Ltd. (ONC) had a gross margin of 87.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is BeOne Medicines Ltd.'s operating margin?

BeOne Medicines Ltd. (ONC) had an operating margin of 8.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is BeOne Medicines Ltd.'s net profit margin?

BeOne Medicines Ltd. (ONC) had a net profit margin of 5.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is BeOne Medicines Ltd.'s return on equity (ROE)?

BeOne Medicines Ltd. (ONC) has a return on equity of 6.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is BeOne Medicines Ltd.'s free cash flow?

BeOne Medicines Ltd. (ONC) generated $941.7M in free cash flow during fiscal year 2025. This represents a 248.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is BeOne Medicines Ltd.'s operating cash flow?

BeOne Medicines Ltd. (ONC) generated $1.1B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are BeOne Medicines Ltd.'s total assets?

BeOne Medicines Ltd. (ONC) had $8.2B in total assets as of fiscal year 2025, including both current and long-term assets.

What are BeOne Medicines Ltd.'s capital expenditures?

BeOne Medicines Ltd. (ONC) invested $185.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does BeOne Medicines Ltd. spend on research and development?

BeOne Medicines Ltd. (ONC) invested $2.1B in research and development during fiscal year 2025.

How many shares does BeOne Medicines Ltd. have outstanding?

BeOne Medicines Ltd. (ONC) had 1.44B shares outstanding as of fiscal year 2025.

What is BeOne Medicines Ltd.'s current ratio?

BeOne Medicines Ltd. (ONC) had a current ratio of 3.41 as of fiscal year 2025, which is generally considered healthy.

What is BeOne Medicines Ltd.'s debt-to-equity ratio?

BeOne Medicines Ltd. (ONC) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is BeOne Medicines Ltd.'s return on assets (ROA)?

BeOne Medicines Ltd. (ONC) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is BeOne Medicines Ltd.'s Altman Z-Score?

BeOne Medicines Ltd. (ONC) has an Altman Z-Score of 5.46, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is BeOne Medicines Ltd.'s Piotroski F-Score?

BeOne Medicines Ltd. (ONC) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are BeOne Medicines Ltd.'s earnings high quality?

BeOne Medicines Ltd. (ONC) has an earnings quality ratio of 3.93x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can BeOne Medicines Ltd. cover its interest payments?

BeOne Medicines Ltd. (ONC) has an interest coverage ratio of 9.0x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is BeOne Medicines Ltd.?

BeOne Medicines Ltd. (ONC) scores 67 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.